<p>Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone minera
<img src="https://fxopen.com/blog/en/content/images/2023/11/EURO-STOXX-50.jpg" alt="Market Analysis: Morgan Stanley Analysts Raise Forecasts for S&P 500" /><p>A
Leave a Comment